, Volume 5, Issue 3, pp 207-214

Prostate cancer in Rochester, Minnesota (USA), from 1935 to 1989: increases in incidence related to more complete ascertainment

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Prostate cancer incidence among White men in the United States climbed steadily from 45 per 105 person-years (PY) during 1945–54 to 102 per 105 PYs in 1988. To determine whether this increase might be the result of changing diagnostic practices, we examined trends in incidence and method of diagnosis in Rochester, Minnesota (US), from 1935 to 1989. We found a parallel increase in Rochester in non-autopsy diagnoses from 44 (95 percent confidence interval [CI]=29–58) cases per 105 PYs in 1935–44 to 71 (CI=52–89) cases per 105 PYs in 1985–87 which was driven by diagnoses prompted by digital rectal examination. There was no evidence that an increasing proportion of cases was found as the result of procedures to treat the symptoms of benign prostatic hyperplasia. Including autopsy diagnoses, incidence was stable over this extended interval and was 77 per 105 PYs (CI=58–97) in 1935–44 and 72 per 105 PYs (CI=53–91) in 1985–87. Incidence more than doubled after introduction of diagnostic serum prostate-specific antigen (PSA) assay and was 179 per 105 PYs (CI=145–214) in 1988–89. We conclude that prostate-cancer incidence rates are influenced strongly by diagnostic practices and that national increases could reflect, to a large extent, more complete and earlier ascertainment rather than more frequent disease.

This project is funded partially by a grant from Merck Research Laboratories, by Rochester Epidemiology Project Grant AM-30582 from the National Institutes of Health, and by Grant NS531153 from the US National Institutes of Health.